Clinical Trial Update: Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

View source ↗

Summary

This update notes that Olezarsen has been approved for marketing under an Early Access Program for patients with Familial Chylomicronemia Syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome

Drugs mentioned

• Olezarsen (olezarsen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Familial Chylomicronemia Syndrome | Status: APPROVED_FOR_MARKETING